search
Back to results

Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors (CAVACI)

Primary Purpose

Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Cardiology consultation
Chest Computed Tomography (CT) without contrast
Non-invasive endothelial function tests
Electrocardiogram
Extra serum sample (7.5 mL)
Sponsored by
Algemeen Ziekenhuis Maria Middelares
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cancer focused on measuring Cardio-oncology, Immune-related adverse event, Immune checkpoint inhibitor, Myocarditis, Troponin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Have a solid tumour and will receive one of the following therapies based on current evidence based clinical guidelines: anti-programmed cell death protein-1 (PD-1), anti-programmed cell death ligand-1 (PD-L1) and/or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy Be literate in Dutch or English Exclusion Criteria: Prior treatment with immunotherapy (immune checkpoint inhibitors, T-cell transfer therapy, cancer treatment vaccines or immune system modulators). Patients who will receive ICIs in combination with an additional systemic anti-cancer regimen (chemotherapy, tyrosine kinase inhibitors,…). Having a known history of human immunodeficiency virus (HIV) infection. Having a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as detectable RNA via qualitative nucleic acid testing) infection. Having a diagnosis of immunodeficiency or is receiving chronic/active systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)

Sites / Locations

  • AZ Sint-Vincentius DeinzeRecruiting
  • Algemeen Ziekenhuis Maria MiddelaresRecruiting
  • AZ Sint-Elisabeth ZottegemRecruiting
  • Antwerp University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors

Arm Description

Patients are treated as standard of care

Outcomes

Primary Outcome Measures

The incidence of an elevated hs-TnT above the ULN if the baseline value was normal; or 1.5 ≥ times baseline if the baseline value was above the ULN within the first three months of treatment. The maximum measured value will be taken into account.
For the primary endpoint, the cumulative incidence of troponin elevation will be calculated with death as a competing risk. Cumulative incidences and corresponding 95% confidence intervals will be reported and a cumulative incidence plot will be used to visualize the results.

Secondary Outcome Measures

The incidence of hs-TnT/NT-proBNP elevations at 6, 12, and 24 months.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
The incidence of hs-TnT/NT-proBNP elevations at baseline, 3, 6, 12, and 24 months.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Evolution of hs-TnT/NT-proBNP in 24 months compared to baseline.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Evolution of transthoracic 3D echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Evolution of electrocardiography parameters (rhythm, heart axis, PQ interval, QRS duration, bundle branch block, QT interval, RR interval, pathological Q's, left ventricular hypertrophy and STT segments) at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and transthoracic echocardiography parameters at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and electrocardiography (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) parameters at baseline, 3, 6, 12, and 24 months.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Cumulative incidence of cardiovascular (CV) abnormalities at 3, 6, 12, and 24 months based on the CARDIOTOX classification system of Sendón et al., with the inclusion of pericardial effusion and new arrhythmias.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Association between the evolution of troponin/NT-proBNP and CV abnormalities (as classified based on the CARDIOTOX classification for myocardial injury including cardiac biomarkers, symptoms, LVEF, LA area, LVESV, GLS and diastolic function).
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Cumulative incidence of MACEs at 3, 6, 12, and 24 months. MACEs were defined as the composite outcome of nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure (HF) and cardiac revascularization, and CV death.
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Overall survival.
Cumulative incidences and 95% confidence intervals
Association between the evolution of troponin/NT-proBNP and MACEs over a period of two years. Nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure, cardiac revascularization and CV death will be combined to report MACEs.
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
The difference in the evolution of hs-TnT/NT-proBNP between combination therapy and monotherapy over a period of two years.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The difference in the evolution of transthoracic echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) between combination therapy and monotherapy over a period of two years.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The difference in the evolution of electrocardiography parameters (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) between combination therapy and monotherapy.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and troponin.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and NT-proBNP.
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Agreement between hs-TnT and hs-TnI levels at baseline, 3, 6, 12, and 24 months.
Bland-Altman curves and intraclass correlation coefficient (ICC) based on a two-way mixed effects model. The ICC and 95% confidence interval will be reported.
The proportion of severe immune-related non-CV toxicities (grades 3-5).
Proportions and 95% confidence interval
Association between the evolution of troponin/NT-proBNP and severe immune-related non-CV toxicities (grades 3-5, e.g. pneumonitis, colitis, thyroiditis, etc. according to the CTCAE criteria).
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between the evolution of troponin/NT-proBNP and overall survival.
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Association between the evolution of troponin and diastolic function (based on the recommendations listed in https://doi.org/10.1016/j.echo.2016.01.011, mitral inflow, tissue doppler imaging parameters).
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Calcium score at baseline, 12 months, and 24 months.
Proportions and 95% confidence interval
Peripheral vascular function at baseline, 3 months, 6 months, 12 months and 24 months.
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter. Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values
Association between the evolution of troponin and calcium score.
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter. Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values

Full Information

First Posted
December 9, 2022
Last Updated
May 30, 2023
Sponsor
Algemeen Ziekenhuis Maria Middelares
search

1. Study Identification

Unique Protocol Identification Number
NCT05699915
Brief Title
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
Acronym
CAVACI
Official Title
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors: a Prospective Multicentre Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 7, 2022 (Actual)
Primary Completion Date
November 30, 2024 (Anticipated)
Study Completion Date
November 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Algemeen Ziekenhuis Maria Middelares

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this prospective, multicentre study is to investigate short- and long-term cardiovascular effects in cancer patients treated with immune checkpoint inhibitors (ICIs). The main question[s] it aims to answer are: To investigate troponin and NT-proBNP values in patients receiving ICIs and their association with ICI-induced CV abnormalities and MACEs. Study the calcium score, systolic, and diastolic (dys)function. Evaluate associations between patient/disease characteristics / transthoracic echocardiography parameters / electrocardiography parameters and troponin / NT-proBNP levels. Participants will be closely monitored by performing the following additional visits and testing: Chest CT scan prior to treatment start, after 12 and 24 months. Consultation with a cardiologist at baseline, 3, 6, 12 and 24 months, who will perform an electrocardiogram and echocardiogram. One additional blood sample prior to treatment start, after 3, 6, 12 and 24 months. An extra blood sample could be taken in case of sudden heart problems. Non-invasive endothelial function tests prior to treatment start, after 12 and 24 months.
Detailed Description
The increasing use of immune checkpoint inhibitors (ICIs) in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of cardiovascular immune related adverse events (irAEs). The current guidelines are based on anecdotal evidence and expert opinions due to the lack of solid data and prospective studies. Therefore, cardiac monitoring, in patients receiving ICIs, is often not implemented by oncologists as many questions remain unanswered. Hence, the urgent need to investigate the possible short and long term cardiovascular effects of ICIs. The investigators developed a multicentre, prospective study in which patients with a solid tumour eligible for ICI treatment will be enrolled. The study exists of routine investigations of blood parameters (troponin and (N-terminal) brain-type natriuretic peptide levels in particular) and a thorough cardiovascular follow-up on fixed time points during a period of two years. The cardiovascular follow-up consists of continuous remote patient monitoring, routine cardiology consultations including electrocardiograms, transthoracic echocardiograms, CT-scans for calcium scoring and non-invasive endothelial function tests. Associations between these blood parameters and short and long term cardiovascular irAEs will be statistically analysed. This project will allow for a better estimate of the incidence of both short and long-term cardiovascular irAEs in a 'real world' patient population receiving ICIs. If the investigators are able to accurately predict and detect short- and long-term cardiovascular irAEs in an early (and subclinical) stage by correct implementation and interpretation of existing cardiac markers, they could be managed early on in a more effective manner.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable, Immune Checkpoint Inhibitor-Related Myocarditis, Diastolic Dysfunction, Atherosclerosis, Cardiotoxicity
Keywords
Cardio-oncology, Immune-related adverse event, Immune checkpoint inhibitor, Myocarditis, Troponin

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
276 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors
Arm Type
Other
Arm Description
Patients are treated as standard of care
Intervention Type
Procedure
Intervention Name(s)
Cardiology consultation
Intervention Description
Electrocardiogram (ECG). Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio > 15 and left atrial (LA) area > 30 cm2.
Intervention Type
Diagnostic Test
Intervention Name(s)
Chest Computed Tomography (CT) without contrast
Other Intervention Name(s)
Cardiac CT
Intervention Description
Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
Intervention Type
Procedure
Intervention Name(s)
Non-invasive endothelial function tests
Other Intervention Name(s)
Flow mediated dilatation (FMD), Peripheral arterial tonometry (PAT)
Intervention Description
FMD PAT This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues.
Intervention Type
Procedure
Intervention Name(s)
Electrocardiogram
Other Intervention Name(s)
ECG
Intervention Description
An ECG will be taken prior to each ICI cycle during the first three months of treatment.
Intervention Type
Diagnostic Test
Intervention Name(s)
Extra serum sample (7.5 mL)
Intervention Description
An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
Primary Outcome Measure Information:
Title
The incidence of an elevated hs-TnT above the ULN if the baseline value was normal; or 1.5 ≥ times baseline if the baseline value was above the ULN within the first three months of treatment. The maximum measured value will be taken into account.
Description
For the primary endpoint, the cumulative incidence of troponin elevation will be calculated with death as a competing risk. Cumulative incidences and corresponding 95% confidence intervals will be reported and a cumulative incidence plot will be used to visualize the results.
Time Frame
Preliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and 3 months after last patient is included.
Secondary Outcome Measure Information:
Title
The incidence of hs-TnT/NT-proBNP elevations at 6, 12, and 24 months.
Description
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Time Frame
Through study completion, an average of 1 year
Title
The incidence of hs-TnT/NT-proBNP elevations at baseline, 3, 6, 12, and 24 months.
Description
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Time Frame
Preliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Evolution of hs-TnT/NT-proBNP in 24 months compared to baseline.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Time Frame
Through study completion, an average of 1 year
Title
Evolution of transthoracic 3D echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) at baseline, 3, 6, 12, and 24 months.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Evolution of electrocardiography parameters (rhythm, heart axis, PQ interval, QRS duration, bundle branch block, QT interval, RR interval, pathological Q's, left ventricular hypertrophy and STT segments) at baseline, 3, 6, 12, and 24 months.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and transthoracic echocardiography parameters at baseline, 3, 6, 12, and 24 months.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and electrocardiography (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) parameters at baseline, 3, 6, 12, and 24 months.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Cumulative incidence of cardiovascular (CV) abnormalities at 3, 6, 12, and 24 months based on the CARDIOTOX classification system of Sendón et al., with the inclusion of pericardial effusion and new arrhythmias.
Description
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Time Frame
Through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and CV abnormalities (as classified based on the CARDIOTOX classification for myocardial injury including cardiac biomarkers, symptoms, LVEF, LA area, LVESV, GLS and diastolic function).
Description
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Time Frame
Through study completion, an average of 1 year
Title
Cumulative incidence of MACEs at 3, 6, 12, and 24 months. MACEs were defined as the composite outcome of nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure (HF) and cardiac revascularization, and CV death.
Description
Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Time Frame
Through study completion, an average of 1 year
Title
Overall survival.
Description
Cumulative incidences and 95% confidence intervals
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and MACEs over a period of two years. Nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure, cardiac revascularization and CV death will be combined to report MACEs.
Description
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Time Frame
Through study completion, an average of 1 year
Title
The difference in the evolution of hs-TnT/NT-proBNP between combination therapy and monotherapy over a period of two years.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
The difference in the evolution of transthoracic echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) between combination therapy and monotherapy over a period of two years.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
The difference in the evolution of electrocardiography parameters (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) between combination therapy and monotherapy.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and troponin.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and NT-proBNP.
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
Agreement between hs-TnT and hs-TnI levels at baseline, 3, 6, 12, and 24 months.
Description
Bland-Altman curves and intraclass correlation coefficient (ICC) based on a two-way mixed effects model. The ICC and 95% confidence interval will be reported.
Time Frame
reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year
Title
The proportion of severe immune-related non-CV toxicities (grades 3-5).
Description
Proportions and 95% confidence interval
Time Frame
Through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and severe immune-related non-CV toxicities (grades 3-5, e.g. pneumonitis, colitis, thyroiditis, etc. according to the CTCAE criteria).
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
Association between the evolution of troponin/NT-proBNP and overall survival.
Description
Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Time Frame
Through study completion, an average of 1 year
Title
Association between the evolution of troponin and diastolic function (based on the recommendations listed in https://doi.org/10.1016/j.echo.2016.01.011, mitral inflow, tissue doppler imaging parameters).
Description
Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Time Frame
Through study completion, an average of 1 year
Title
Calcium score at baseline, 12 months, and 24 months.
Description
Proportions and 95% confidence interval
Time Frame
Through study completion, an average of 1 year
Title
Peripheral vascular function at baseline, 3 months, 6 months, 12 months and 24 months.
Description
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter. Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values
Time Frame
Through study completion, an average of 1 year
Title
Association between the evolution of troponin and calcium score.
Description
Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter. Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values
Time Frame
Through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have a solid tumour and will receive one of the following therapies based on current evidence based clinical guidelines: anti-programmed cell death protein-1 (PD-1), anti-programmed cell death ligand-1 (PD-L1) and/or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy Be literate in Dutch or English Exclusion Criteria: Prior treatment with immunotherapy (immune checkpoint inhibitors, T-cell transfer therapy, cancer treatment vaccines or immune system modulators). Patients who will receive ICIs in combination with an additional systemic anti-cancer regimen (chemotherapy, tyrosine kinase inhibitors,…). Having a known history of human immunodeficiency virus (HIV) infection. Having a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as detectable RNA via qualitative nucleic acid testing) infection. Having a diagnosis of immunodeficiency or is receiving chronic/active systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christof Vulsteke, Prof
Phone
+3292469522
Email
Christof.Vulsteke@azmmsj.be
First Name & Middle Initial & Last Name or Official Title & Degree
Danielle Delombaerde, PharmD
Phone
+3292469511
Email
Danielle.Delombaerde@azmmsj.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christof Vulsteke, Prof
Organizational Affiliation
Algemeen Ziekenhuis Maria Middelares
Official's Role
Principal Investigator
Facility Information:
Facility Name
AZ Sint-Vincentius Deinze
City
Deinze
State/Province
East-Flanders
ZIP/Postal Code
9800
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christof Vulsteke, Prof
Phone
+3292469522
Email
Christof.Vulsteke@azmmsj.be
Facility Name
Algemeen Ziekenhuis Maria Middelares
City
Ghent
State/Province
East-Flanders
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christof Vulsteke, Prof
Phone
+3292469522
Email
Christof.Vulsteke@azmmsj.be
First Name & Middle Initial & Last Name & Degree
Danielle Delombaerde, PharmD
Phone
+3292469511
Email
Danielle.Delombaerde@azmmsj.be
Facility Name
AZ Sint-Elisabeth Zottegem
City
Zottegem
State/Province
East-Flanders
ZIP/Postal Code
9620
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christof Vulsteke, Prof
Phone
+3292469522
Email
Christof.Vulsteke@azmmsj.be
Facility Name
Antwerp University Hospital
City
Antwerp
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Prenen, Prof
Email
Hans.Prenen@uza.be
First Name & Middle Initial & Last Name & Degree
Sanne Wouters
Phone
+32 3 821 24 41
Email
Sanne.Wouters@uza.be
First Name & Middle Initial & Last Name & Degree
Hans Prenen, Prof
First Name & Middle Initial & Last Name & Degree
Constantijn Franssen, Dr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

We'll reach out to this number within 24 hrs